(Total Views: 567)
Posted On: 10/31/2019 5:17:33 PM
Post# of 154780
8-k out, 0.9m proceeds
On October 25, 2019 and October 29, 2019, CytoDyn Inc. (the “Company”), issued in private placements to accredited investors an aggregate of 918 shares of its Series C Convertible Preferred Stock, par value $0.001 per share, with an initial stated value of $1,000 per share (the “Series C Preferred Stock”), together with warrants to purchase an aggregate of up to 2,295,000 shares of its common stock, par value $0.001 (“Common Stock”) per share, with an initial exercise price of $0.30 per share (the “Series C Warrants”) for aggregate gross proceeds to the Company of approximately $0.9 million (the “Series C Offering”).
On October 25, 2019 and October 29, 2019, CytoDyn Inc. (the “Company”), issued in private placements to accredited investors an aggregate of 918 shares of its Series C Convertible Preferred Stock, par value $0.001 per share, with an initial stated value of $1,000 per share (the “Series C Preferred Stock”), together with warrants to purchase an aggregate of up to 2,295,000 shares of its common stock, par value $0.001 (“Common Stock”) per share, with an initial exercise price of $0.30 per share (the “Series C Warrants”) for aggregate gross proceeds to the Company of approximately $0.9 million (the “Series C Offering”).
(2)
(1)
